ERBB2 and non-small cell lung carcinoma: While another retrospective study reported the inferior outcomes of HER2-mutant NSCLC compared with ALK/ROS1-rearranged group, with a median PFS of 5.1 months in pemetrexed-based first-line chemotherapy.